相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
2
100.0%
暂无批准数据
- WRN inhibitors represent a fast-emerging precision oncology segment targeting DNA repair vulnerabilities in microsatellite instability-high (MSI-H) tumors through synthetic lethality mechanisms. - Multiple promising candidates including NDI-219216, GSK4418959, HRO761, and RO7589831 are advancing through early-stage clinical trials, demonstrating potent anti-tumor activity and strong selectivity for MSI tumors. - The market is expected to surge significantly by 2040, driven by advances in biomarker-driven patient stratification and compelling preclinical data showing tumor regression in patient-derived xenograft models. - Leading pharmaceutical companies including Nimbus Therapeutics, GlaxoSmithKline, Ideaya Biosciences, and Novartis are developing these novel therapies for colorectal, endometrial, and other solid tumors.
- MOMA Therapeutics has dosed the first patient in a Phase 1 clinical trial of MOMA-341, a novel oral Werner helicase inhibitor targeting advanced or metastatic solid tumors with high microsatellite instability. - The drug represents a potentially best-in-class therapeutic with a novel chemical scaffold discovered through MOMA's proprietary KNOMATIC platform, designed to exploit Werner helicase dependency in MSI-H/dMMR tumor cells. - The global multi-center trial will evaluate MOMA-341 as monotherapy and in combination with chemotherapy or immunotherapy, with initial monotherapy data expected in mid-2026. - This marks MOMA's second clinical entry within a year, following their Pol θ helicase inhibitor MOMA-313, demonstrating the company's rapid pipeline advancement in precision oncology.
- MOMA Therapeutics has dosed the first patient in a Phase 1 clinical trial evaluating MOMA-313, a highly potent and selective oral polymerase theta helicase inhibitor with best-in-class potential. - The trial will assess MOMA-313 as monotherapy and in combination with PARP inhibitor olaparib for patients with solid tumors harboring DNA repair gene alterations, including prostate, pancreatic, and breast cancers. - The company simultaneously selected MOMA-341, a Werner helicase inhibitor, as its second development candidate for microsatellite instability cancers, with IND filing anticipated in Q1 2025. - Both drug candidates were developed using MOMA's proprietary KNOMATIC platform, which targets highly dynamic proteins involved in cancer dependencies.
